SCHEMBL5376312

SCHEMBL5376312

Cc1ccc(S(=O)(=O)c2nc[nH]n2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
AKR1B1 P15121 1/20 0.46
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
ALDH1A1 P00352 2/20 0.42
RAPGEF4 Q8WZA2 1/20 0.42
KMT2A Q03164 5/20 0.41
MAPT P10636 2/20 0.41
MEN1 O00255 1/20 0.41
HSP90AA1 P07900 2/20 0.40
CXCR5 P32302 1/20 0.40
APLNR P35414 1/20 0.40
RAB9A P51151 1/20 0.40
CCR6 P51684 1/20 0.40
GFER P55789 1/20 0.40
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA3 P07451 1/20 0.39
CA6 P23280 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9435542 0.81 HTR6 (0.48) AKR1B1SMN1; SMN2ALDH1A1KMT2AMEN1
SCHEMBL8982451 0.78 AKR1B1 (0.50) AKR1B1HTTALDH1A1MAPTCA1
SCHEMBL22494208 0.78
SCHEMBL9507454 0.76 CA2 (0.46) SMN1; SMN2HTTALDH1A1KMT2AMAPT
SCHEMBL5694176 0.74 TSHR (0.44) ALDH1A1KMT2AMAPTMEN1PAX8
SCHEMBL5957761 0.73 GAA (0.60) GAASMN1; SMN2HTTALDH1A1RAPGEF4
SCHEMBL170033 0.71 GAA (1.00) GAASMN1; SMN2HTTALDH1A1RAPGEF4
SCHEMBL4400955 0.71 GAA (1.00) GAASMN1; SMN2HTTALDH1A1RAPGEF4
SCHEMBL10067072 0.71 GAA (1.00) GAASMN1; SMN2HTTALDH1A1RAPGEF4
SCHEMBL11032457 0.69 GAA (0.54) GAAAKR1B1SMN1; SMN2HTTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7238720-B2 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2007-07-03 US disclosed
EP-1258480-B1 Pharmaceutical use of N-Carbamoylazole derivatives EISAI CO LTD (JP) 2004-11-10 EP disclosed
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI R & D MANAGEMENT CO. LTD. (JP) 2004-09-23 US disclosed
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives EISAI CO., LTD. (JP) 2003-03-27 US disclosed
EP-1258480-A1 Pharmaceutical use of N-Carbamoylazole derivatives Eisai Co., Ltd. (JP) 2002-11-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186153-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 GAA 215/4885AKR1B1 2847/4885SMN1; SMN2 4811/4885
US-20030060494-A1 Pharmaceutical use of N-carbamoylazole derivatives DPP4, DPP3, DPP7 GAA 215/4885AKR1B1 2847/4885SMN1; SMN2 4811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.